Marine algal carotenoids inhibit angiogenesis by down-regulating FGF-2-mediated intracellular signals in vascular endothelial cells

Molecular and Cellular Biochemistry

Volumn 380, Issue 1-2, 2013, Pages 1-9

  Ganesan, Ponesakki ^a,b   Matsubara, Kiminori ^c   Sugawara, Tatsuya ^a   Hirata, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; FGF 2; Fucoxanthin; Marine algae; Siphonaxanthin

Indexed keywords

ANGIOGENESIS INHIBITOR; CAROTENOID; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FUCOXANTHIN; MATRIGEL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SIPHONAXANTHIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; DOWN REGULATION; DRUG ISOLATION; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; MARINE SPECIES; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; CHLOROPHYTA; DOWN-REGULATION; EARLY GROWTH RESPONSE PROTEIN 1; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTRACELLULAR SPACE; MARINE BIOLOGY; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PHYSIOLOGIC; PHAEOPHYTA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; XANTHOPHYLLS;

ALGAE;

EID: 84876395725     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1651-5     Document Type: Article

References (47)

1. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931-10934
2. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
3. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-30
4. Virmani R, Kolodgie FD, Burke AP, Fin AV, Gold HK, Tulenko TN, Wrenn SP, Narula J (2005) Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Atheroscler Thromb Vasc Biol 25:2054-2061
5. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater anti-tumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64:6626-6634
6. Hicklin DJ, Ellis LM (2005) Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027
7. Folkman J (2002) Looking for a good endothelial address. Cancer Cell 1:113-115
8. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309
9. Kerbel RS (2005) Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy revealed. Cancer Cell 8:269-271
10. Ferrara N (1999) Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 237:1-30
11. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248
12. Vinals F, Pouyssegur J (2001) Transforming growth factor β1 (TGF-β1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-α signaling. Mol Cell Biol 21:7218-7230
13. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974
14. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery. Nat Rev 6:273-286
15. Garber K (2002) Angiogenesis inhibitors suffer new setback. Nat Biotechnol 20:1067-1068
16. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795
17. Albini A, Noonan DM, Ferrari N (2007) Molecular pathways for cancer angioprevention. Clin Cancer Res 13:4320-4325
18. Cao Y (2004) Antiangiogenic cancer therapy. Semin Cancer Biol 14:139-145
19. Sagar SM, Yance D, Wong RK (2006) Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer. Curr Oncol 13:14-26
20. Sugawara T, Matsubara K, Akagi R, Mori M, Hirata T (2006) Antiangiogenic activity of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. J Agric Food Chem 54:9805-9810
21. Ganesan P, Matsubara K, Ohkubo T, Tanaka Y, Noda K, Sugawara T, Hirata T (2010) Anti-angiogenic effect of siphonaxanthin from green alga, Codium fragile. Phytomedicine 17:1140-1144
22. Sugawara T, Yamashita K, Asai A, Nagao A, Shiraishi T, Imai I, Hirata T (2009) Esterification of xanthophylls by human intestinal Caco-2 cells. Arch Biochem Biophys 483:205-212
23. Ganesan P, Noda K, Manabe Y, Ohkubo T, Tanaka Y, Maoka T, Sugawara T, Hirata T (2011) Siphonaxanthin, a marine algal carotenoids from green algae, effectively induces apoptosis in human leukemia (HL-60) cells. Biochim Biophys Acta 1810:497-503
24. Matsubara K, Xue C, Zhao X, Mori M, Sugawara T, Hirata T (2005) Effects of middle molecular weight fucoidans on in vitro and ex vivo angiogenesis of endothelial cells. Int J Mol Med 15:695-699
25. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M (1984) Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 223:1296-1299
26. Cross MJ, Claesson-Welsh L (2001) FGF and VEGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22:201-207
27. Wang D, Mayo MW Jr, Balswin AS (1997) Basic fibroblast growth factor transcriptional autoregulation requires Egr-1. Oncogene 14:2291-2299
28. Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM (1999) Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am J Pathol 154:937-944
29. Montesano R, Orci L, Vassalli P (1983) In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97:1648-1652
30. Dailey L, Ambrosetti D, Mansukhani A, Basilico C (2005) Mechanisms underlying differential responses to FGF-signaling. Cytokine Growth Factor Rev 16:233-247
31. Feng X, Ofstad W, Hawkins D (2010) Antiangiogenesis therapy: a new strategy for cancer treatment. US Pharm 35:4-9
32. Al-Jamal KT, Al-Jamal WT, Akerman S, Podesta JE, Yilmazer A, Turton JA, Bianco A, Vargesson N, Kanthou C, Florence AT, Tozer GM, Kostarelos K (2010) Systemic anti-angiogenic activity of cationic poly-l-lysine dendrimer delays tumor growth. Proc Natl Acad Sci USA 107:3966-3971
33. Turner N, Grose R (2010) Fibroblast growth factor signaling: from development to cancer. Nat Rev 10:116-129
34. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676
35. Fahmy RG, Dass CR, Sun L, Chesterman CN, Khachigian LM (2003) Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 9:1026-1032
36. Altomare DA, Testa JR (2005) Perturbation of the AKT signaling pathway in human cancer. Oncogene 24:7455-7464
37. Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:139-149
38. Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA (2003) Differential αv integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 162:933-943
39. Eliceiri BP, Klemke R, Strömblad S, Cheresh DA (1998) Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 140:1255-1263
40. Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 14:381-395
41. Kok TW, Yue PYK, Mak NK, Fan TPD, Liu L, Wong RNS (2005) The anti-angiogenic effect of sinomenine. Angiogenesis 8:3-12
42. Hussain S, Slevin M, Matou S, Ahmed N, Choudhary MI, Ranjit R, West D, Gaffney J (2008) Anti-angiogenic activity of sesterterpenes: natural product inhibitors of FGF-2-induced angiogenesis. Angiogenesis 11:245-256
43. Peng C, Pan S, Lee K, Bastow KF, Tend C (2008) Molecular mechanism of the inhibitory effect of KS-5 on FGF-2-induced angiogenesis in vitro and in vivo. Cancer Lett 263:114-121
44. Miyazawa T, Shibata A, Sookwong P, Kawakami Y, Eitsuka T, Asai A, Oikawa S, Nakagawa K (2009) Anti-angiogenic and anti-cancer potential of unsaturated vitamin E (tocotrienol). J Nutr Biochem 20:79-86
45. Sugawara T, Baskaran V, Tsuzuki W, Nagao A (2002) Brown algae fucoxanthin is hydrolyzed to fucoxanthinol during absorption by Caco-2 human intestinal cells and mice. J Nutr 132:946-951
46. Asai A, Sugawara T, Ono H, Nagao A (2004) Biotransformation of fucoxanthinol to amarouciaxanthin A in mice and HepG2 cells: formation and cytotoxicity of fucoxanthin metabolites. Drug Metab Dispos 32:205-211
47. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932-936